title: Efficacy of a new spot-on formulation of selamectin plus sarolaner in the treatment of Otodectes cynotis in cats.
abstract: The efficacy of a new spot-on formulation of selamectin/sarolaner was evaluated against induced Otodectes cynotis infestations in cats in two randomized, blinded studies. Fourteen and 16 cats were randomly assigned to treatment groups in Studies 1 and 2, respectively. On Day 0, animals were either treated with placebo or with the spot-on formulation at the minimal dose of 6.0mg selamectin and 1.0mg sarolaner per kg bodyweight. Treatments were administered topically at the base of the neck. Presence of live mites was evaluated 14days after treatment administration by otoscopic examination and total live mite counts (adults plus immature) were conducted on Day 30 by ear lavage. Efficacy was calculated based on the reduction of mean total live mite counts on Day 30 in the selamectin/sarolaner-treated group versus the placebo-treated group. There were no treatment-related adverse reactions during the studies, apart from one cat in each treatment group with alopecia at the administration site. In both studies combined, live mites were present on Day 14, in 14 out of 15 cats in the placebo-treated groups and in 2 out of 15 cats in the selamectin/sarolaner-treated groups. On Day 30, the arithmetic mean live mite counts were 576.9 and 875.8 in the placebo-treated groups and 5.8 and 4.7 in the selamectin/sarolaner-treated groups, in Studies 1 and 2, respectively. The live mite counts were significantly (P≤0.0021) lower in the selamectin/sarolaner-treated groups compared to the placebo-treated groups with efficacies of 99.2% and 99.3%, in Studies 1 and 2 respectively. A single administration of a new spot-on formulation of selamectin/sarolaner at the minimum dose was safe and highly efficacious in the treatment of ear mite infestations in cats.
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20, Zaventem, B-1930, Belgium. Electronic address: csilla.becskei@zoetis.com.
authors.forename: Csilla
authors.initials: C
authors.lastname: Becskei
authors.affiliation: East Tennessee Clinical Research Inc., 80 Copper Ridge Farm Road, Rockwood, TN 37854, USA.
authors.forename: Craig
authors.initials: C
authors.lastname: Reinemeyer
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI 49007 USA.
authors.forename: Vickie L
authors.initials: VL
authors.lastname: King
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20, Zaventem, B-1930, Belgium.
authors.forename: Dan
authors.initials: D
authors.lastname: Lin
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI 49007 USA.
authors.forename: Melanie R
authors.initials: MR
authors.lastname: Myers
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage Street, Kalamazoo, MI 49007 USA.
authors.forename: Adriano F
authors.initials: AF
authors.lastname: Vatta
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000977:Antiparasitic Agents / Q000008:administration & dosage; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D005260:Female; D007555:Isoxazoles / Q000008:administration & dosage*; D007559:Ivermectin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008297:Male; D008924:Mite Infestations / Q000188:drug therapy / Q000662:veterinary*; D059208:Parasite Load; D040042:Psoroptidae; D011897:Random Allocation; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000977:Antiparasitic Agents; D007555:Isoxazoles; D007559:Ivermectin; C414354:selamectin
keywords: Cat; Ear mites; Otodectes cynotis; Revolution; Sarolaner; Selamectin; Stronghold